Through analyses of blood samples from hundreds of patients, researchers have developed a highly accurate test for diagnosing amyotrophic lateral sclerosis (ALS). The test is based on a unique protein signature in the blood that may be able to detect ALS-related changes up to 10 years before symptoms of…
Coya Therapeutics is preparing to launch a Phase 2 clinical trial in the U.S. to test its COYA 302 as an amyotrophic lateral sclerosis (ALS) treatment. The company said the U.S. Food and Drug Administration accepted its investigational new drug (IND) application after it submitted additional data the agency…
New research is bringing mind-to-speech technology a step closer to reality for people with paralysis, including those with amyotrophic lateral sclerosis (ALS) who lose the ability to speak. A proof-of-principle study shows that a brain-computer interface (BCI) can translate a person’s silent thoughts into spoken words and could provide…
A retrospective analysis using data from two clinical studies and their extension periods showed that Radicava ORS, an oral formulation of edaravone, slows functional decline and helps adults with amyotrophic lateral sclerosis (ALS) live longer. “This analysis provides additional data to help characterize functional outcomes and potential impact of…
A veterinary medication repurposed as a treatment for amyotrophic lateral sclerosis (ALS) helped patients live longer and slowed disease progression in a long-term clinical trial. The drug, NUZ-001 from Neurizon Therapeutics, was generally safe and well tolerated in the open-label extension (NCT06177431) study, which tested the treatment in…
China’s National Medical Products Administration has granted Sineugene Therapeutics permission to begin clinical trials of its gene therapy SNUG01 in people with amyotrophic lateral sclerosis (ALS), clearing the way for clinical trials. The announcement follows a similar decision by the U.S. Food and Drug Administration (FDA). It sets…
The second edition of ALS Nexus — a conference hosted earlier this month in Dallas by the ALS Association — brought together people from across the amyotrophic lateral sclerosis (ALS) community to connect with each other, celebrate recent advances, and share hope for the future. “What really…
Due to a lack of resources and personnel, the U.S. Food and Drug Administration (FDA) has delayed its decision on whether or not to lift the clinical hold on NUZ-001, Neurizon Therapeutics’ investigational therapy for amyotrophic lateral sclerosis (ALS), the developer announced. A decision from the regulatory agency…
An experimental oral therapy for amyotrophic lateral sclerosis (ALS) that’s being developed by Athira Pharma was shown to be safe and well tolerated in healthy volunteers who took part in a Phase 1 clinical trial, and the treatment entered the participants’ brain and spinal cords at dose-proportional levels.
Genetically reprogramming nerve cells to reverse aging may be a viable strategy for treating amyotrophic lateral sclerosis (ALS), a mouse study showed. Researchers found that a gene therapy made the mice’s nerve cells younger and more resilient, which delayed the onset of ALS symptoms. “Our hope is that this…
